SOURCE: Dynavax Technologies

Dynavax Technologies

May 29, 2012 16:00 ET

Dynavax to Present at the Jefferies 2012 Global Healthcare Conference

BERKELEY, CA--(Marketwire - May 29, 2012) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to present at the Jefferies 2012 Global Healthcare Conference in New York on Tuesday, June 5, at 9:30 a.m. EDT (6:30 a.m. PDT).

Dino Dina, M.D., Chief Executive Officer of Dynavax, will provide a corporate overview presentation. To access the slide presentation, live webcast, and subsequent archived recording, please visit Dynavax's website at

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's lead product candidate is HEPLISAV™, a Phase 3 investigational adult hepatitis B vaccine designed to provide higher and earlier protection with fewer doses than currently licensed vaccines. A U.S. BLA for HEPLISAV has been submitted to the FDA. For more information visit

Contact Information

  • Contact:
    Michael Ostrach
    Vice President and Chief Business Officer
    Email Contact